Virtual Reality and Spinal Stimulation to Improve Arm Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05065437|
Recruitment Status : Withdrawn (No IRB application has been prepared for this study and other studies have taken priority. The study team will not be working on this study for the foreseeable future.)
First Posted : October 4, 2021
Last Update Posted : July 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Tetraplegia||Other: Active (Virtual reality and spinal stimulation)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Immersive Virtual Reality and Noninvasive Spinal Stimulation to Promote Arm Function in Individuals With Tetraplegia|
|Estimated Study Start Date :||June 2022|
|Estimated Primary Completion Date :||January 1, 2024|
|Estimated Study Completion Date :||January 1, 2024|
Experimental: Virtual reality and spinal stimulation
Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.
Other: Active (Virtual reality and spinal stimulation)
Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
- Change in medical status [ Time Frame: Baseline to post intervention, approximately 4 weeks ]Safety of the intervention will be assessed as the number of participants who experience a reduction in medical stability and/or functionality from before to after the intervention.
- Acceptability of the treatment [ Time Frame: Post intervention, approximately 4 weeks ]Acceptability of the treatment will be assessed using the Treatment Evaluation Inventory-Short Form. Items are scored using a 5-point scale, with 1 equaling strongly disagree and 5 equaling strongly agree. TEI-SF scores can range from 9 to 45, with higher scores representing greater acceptance of the treatment.
- Usability of the treatment [ Time Frame: Post intervention, approximately 4 weeks ]Usability of the treatment will be assessed using the Usefulness, Satisfaction, and Ease of Use (USE) Questionnaire. Items are rated on a seven-point scale ranging from strongly disagree to strongly agree. A higher scale score indicates higher usability.
- Change in affect [ Time Frame: Baseline to post intervention, approximately 4 weeks ]Affect will be assessed using the Positive and Negative Affect Schedule (PANAS). The PANAS is a 20-item measure that measures the intensity of 20 emotions on a 0-5 scale ranging from "not at all" to "extremely."
- Change in current pain intensity [ Time Frame: Baseline to post intervention, approximately 4 weeks ]Current pain intensity will be assessed using a Numeric Rating Scale (NRS). Participants will rate their current pain (multiple types of pain) on a 0-10 scale (0 = "no pain" and 10 = "worst possible pain").
- Change in clinical muscle strength [ Time Frame: Baseline to post intervention, approximately 4 weeks ]Clinical muscle strength will be assessed using the American Spinal Cord Injury Association (ASIA) Upper Extremity Motor Score. Motor strength is rated on a 6 point scale with higher ratings indicating greater strength.
- Change in upper limb function [ Time Frame: Baseline to post intervention, approximately 4 weeks ]Upper limb function will be assessed using the Spinal Cord Independence Measure (SCIM). The SCIM is composed of 19 items that assess function. SCIM scores range from 0 to 100.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- incomplete low tetraplegia (C5-8; [ASIA] classification B-D),
- free of contraindications to transspinal stimulation,
- more than one-year post-injury,
- stable medication regimen for the past month,
- utilization of wheelchair as a primary mode of mobility (>75% of the time). -
- Neurologic injury other than spinal cord injury
- severe medical illness.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05065437
|United States, Virginia|
|Virginia Commonwealth University|
|Richmond, Virginia, United States, 23298|
|Principal Investigator:||Carrie Peterson, PhD||Virginia Commonwealth University|
|Responsible Party:||Virginia Commonwealth University|
|Other Study ID Numbers:||
|First Posted:||October 4, 2021 Key Record Dates|
|Last Update Posted:||July 1, 2022|
|Last Verified:||June 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
upper limb function
spinal cord stimulation
Nervous System Diseases